Global Pleural Diseases Therapeutics Market to Reach USD 9.4 Billion by 2033, Growing at a 6.5% CAGR
Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...
Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...
One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...
Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce ...
A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...
Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma ...
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...
FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...
The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
Boehringer Ingelheim was an early adopter of ... It also signs the German pharma company up for myMedidata, a suite of patient-facing technologies aimed at enhancing patient centricity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback